Decellularized dermis allograft for the treatment of venous leg ulceration: the DAVE RCT - Takeaways - MDSpire

Decellularized dermis allograft for the treatment of venous leg ulceration: the DAVE RCT

  • By

  • Sarah Onida

  • Matthew Tan

  • Valeria Balan

  • Francine Heatley

  • Sarrah Peerbux

  • Layla Bolton-Saghdaoui

  • Tristan Lane

  • David Epstein

  • Manjit Gohel

  • John Norrie

  • Robert Lee

  • Richard Lomas

  • Alun H Davies

  • February 17, 2025

  • 0 min

Share

  • 1

    The DAVE RCT assessed the effectiveness of decellularized dermis allografts in treating venous leg ulcers compared to standard care.

  • 2

    Participants included adults with VLUs, venous incompetence, and ulcers present for at least 3 months.

  • 3

    Healing rates at 12 weeks were 5.7% for the intervention group and 15.2% for the control group, indicating no significant benefit from DCD.

  • 4

    The trial was terminated early due to lower-than-expected healing rates in both groups, raising concerns about the sample size.

  • 5

    Decellularized dermis grafts did not improve healing rates for VLUs, and the study could not confirm significant clinical benefits or harms.

Original Source(s)

Decellularized dermis allograft for the treatment of venous leg ulceration: the DAVE RCT

  • by Sarah Onida, Matthew Tan, Valeria Balan, Francine Heatley, Sarrah Peerbux, Layla Bolton-Saghdaoui, Tristan Lane, David Epstein, Manjit Gohel, John Norrie, Robert Lee, Richard Lomas, Alun H Davies

  • February 17, 2025

Related Content

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Advancements in Understanding TWEAK/Fn14 Pathway in the Healing of Chronic Wounds

NPs Top US Jobs List Again

The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.